Amgen prices Repatha in Europe

Amgen Inc. (NASDAQ:AGMN) priced Repatha evolocumab in several European countries. The drug will cost L340.20 ($524.42) for a 28-day supply in the U.K., or about $6,800 a year, compared to EUR 7,293 ($8,180) in Austria and EUR 7,825 ($8,777) in Finland.

Amgen priced the PCSK9 inhibitor at $14,100 annually in the U.S. (see BioCentury Extra, Aug. 27). ...